Skip to content

Reproductive & sexual health

Oxytocin

The natural nonapeptide hormone of labour and lactation, long approved as an IV/IM obstetric medicine.

L5Practice-changingApproved medicineApprovedHigh confidenceLast reviewed 2026-08-23
IVIMNasal· unapproved

Also known as: Pitocin, Syntocinon

Evidence passport

Last reviewed 2026-08-23

Evidence level
L5Practice-changing
Confidence
High confidence
Human efficacy
85/100
Human safety
80/100
Regulatory status
Approved medicine
Development
Approved
Routes
IVIMNasal· unapproved
Evidence base
Includes human data
Furthest stage
Approved
Source curation
Sources fully curated
Clinical maturity
Established obstetric medicine

Overview

Human evidence85/100
Preclinical evidence80/100
Human safety evidence80/100

Clinical maturity: Established obstetric medicine

Routes & formulations

Studied / approved routes

IVIM

Marketed / research routes — never approved

Nasal· unapproved

Approved obstetric use is IV infusion or IM injection in clinical settings. Intranasal oxytocin appears in research studies and research-market products; that work is not the approved medicine and does not support social, mood or bonding claims.

Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.

Peptide lifecycle

  1. Discovery

  2. Preclinical

  3. Phase I

  4. Phase II

  5. Phase III

  6. Approved

Approved

What it is

A nine-amino-acid hormone produced in the hypothalamus that triggers uterine contractions and milk ejection; synthetic oxytocin is one of the oldest peptide medicines still in routine use.

What people claim

  • Induces or augments labour in defined obstetric situations
  • Helps control postpartum bleeding
  • Marketed online for mood, bonding and social effects via nasal sprays

What the evidence actually says

The approved obstetric evidence base is deep and old. Intranasal oxytocin research in psychology is real but inconsistent, and evidence does not transfer from supervised IV obstetric use to wellness nasal sprays.

Human evidence

  • Decades of obstetric trials and clinical use for labelled indications.
  • Intranasal behavioural studies exist but are small and inconsistent.

Preclinical evidence

  • Extensive neuroendocrine pharmacology of the oxytocin system.

Animal and cell findings are Level 1–2 evidence.

Mechanism and pathways

  • Oxytocin-receptor activation in uterine smooth muscle drives contractions; in breast myoepithelial cells it drives milk ejection.

Safety and unknowns

  • Labelled obstetric risks include uterine hyperstimulation and water intoxication with high-volume infusion; use is monitored.
  • Unregulated nasal products carry unknown purity and no approved indication.

Cancer relevance

No concern identified

No established human cancer signal within approved use.

Regulatory status

Approved (e.g. Pitocin) for specific obstetric indications including induction or augmentation of labour and control of postpartum bleeding, given by IV infusion or IM injection under medical supervision.

Evidence grade

L5Practice-changingHigh confidence

Replicated large randomised trials, pivotal Phase 3 programmes, or a major regulatory decision.

What would change our rating?

  • Consistent, replicated human evidence for any non-obstetric claim would be rated on its own merits.

References and sources

Sources fully curated

Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.

Evidence change history

No recorded changes yet. Baseline position set on 2026-08-23.

Related claims we’ve checked

MisleadingL3Early humanRoutes & formulations

“Oxytocin nasal sprays sold online carry the same evidence as medical Pitocin.”

Misleading — the approved evidence belongs to IV/IM obstetric use only.

  • Approved oxytocin (Pitocin) evidence covers supervised IV infusion and IM injection for specific obstetric indications such as labour induction and postpartum bleeding control.
  • Intranasal oxytocin behavioural research is small and inconsistent, and research-market nasal sprays are unapproved products of unknown purity.
  • Evidence is route- and indication-specific: IV obstetric data does not validate wellness nasal-spray claims.
Last reviewed 2026-08-23Compound profile